709. Potential mechanisms of action of VNS in DTD

Abstract

Abstract Background Vagus Nerve Stimulation (VNS) is an established neuromodulation approach with regulatory approvals for chronic, treatment-resistant depression in several jurisdictions and growing interest in its role within Difficult-to-Treat Depression (DTD). DTD emphasizes persistent functional impairment and suboptimal outcomes across sequential evidence-based interventions. Understanding VNS mechanisms is central to identifying who may benefit, how to combine it with pharmacotherapy/psychotherapy, and which biomarkers could guide precision selection. Aims & Objectives This abstract synthesizes potential mechanisms by which VNS may improve depressive symptoms in DTD, focusing on (i) large-scale brain network modulation, (ii) monoaminergic and glutamatergic signaling effects, (iii) neuroplasticity and stress-system recalibration, and (iv) immuno-metabolic and autonomic pathways relevant to chronicity and resistance. Method A mechanistic narrative synthesis is conceptually structured around translational evidence streams: (1) neuroanatomical and electrophysiological mapping of vagal afferent pathways, (2) preclinical studies linking VNS to neurotransmission and plasticity markers, (3) human neuroimaging and electrophysiology examining circuit and network changes, and (4) clinical biomarker studies (autonomic indices, inflammatory markers, endocrine measures) in depression cohorts exposed to VNS. Mechanisms were grouped by plausibility, convergence across modalities, and relevance to known DTD phenotypes (e.g., inflammatory, anhedonic, hyperaroused). Results Converging evidence suggests VNS engages vagal afferents projecting to the nucleus tractus solitarius with downstream influence on the locus coeruleus (noradrenergic) and dorsal raphe (serotonergic) nuclei, thereby modulating arousal, salience processing, and mood regulation. At the systems level, VNS appears to recalibrate cortico-limbic circuitry (including amygdala, hippocampus, anterior cingulate, and prefrontal regions) and may shift maladaptive large-scale network dynamics implicated in DTD—such as excessive default mode coupling, impaired cognitive control, and blunted reward network responsivity. Biologically, VNS is hypothesized to promote synaptic plasticity (e.g., activity-dependent neurotrophic signaling), normalize stress-axis function (HPA regulation), enhance autonomic balance (increased parasympathetic tone/HRV), and attenuate low-grade inflammation via the “cholinergic anti-inflammatory” pathway. These multi-domain effects align with the heterogeneity of DTD, where resistance may reflect distinct mechanistic subtypes rather than a single refractory state. Discussion & Conclusions VNS likely exerts antidepressant effects through coordinated circuit-level and peripheral-to-central mechanisms that target core DTD liabilities: rigid network states, dysregulated arousal, stress sensitization, and immune-autonomic imbalance. A key next step is prospective, biomarker-informed trials testing mechanism-linked enrichment strategies (e.g., inflammatory profiles, autonomic markers, network connectivity signatures) and combination algorithms to optimize sequencing and augmentation in DTD care pathways.